Hospital
Beth Israel Deaconess Medical Center, INC.
Beth Israel Deaconess Medical Center, INC. was paid $270.28M by Medicaid between Jan 2018 and Dec 2024, across 847 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 9.5% of everything it billed.
33Billing provider infoBETH ISRAEL DEACONESS MEDICAL CENTER, INC.
BOSTON, MA 02215
BOSTON, MA 02215
33aNPI1548202641assigned 06/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$270.28M
24GClaims7,802,371
24DCodes billed847
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#5 of 66
Median peer was paid$29.11M
This provider vs. median9.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,114,724 | $34.06M | |
| 2019 | 1,147,076 | $34.45M | |
| 2020 | 931,455 | $27.77M | |
| 2021 | 1,277,877 | $43.03M | |
| 2022 | 1,251,398 | $50.48M | |
| 2023 | 1,172,075 | $45.94M | |
| 2024incomplete | 907,766 | $34.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 9.5% | 183,753 | 160,009 | $25.76M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.8% | 118,831 | 104,654 | $15.77M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 5.2% | 97,649 | 83,567 | $14.10M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.4% | 30,288 | 19,886 | $9.09M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.1% | 312,416 | 239,964 | $8.32M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 21,591 | 17,851 | $7.80M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.8% | 968 | 808 | $7.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 36,504 | 32,930 | $6.82M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 8,878 | 8,750 | $5.13M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.9% | 42,899 | 39,488 | $5.06M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.8% | 3,108 | 2,735 | $4.93M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.7% | 7,290 | 7,165 | $4.66M |
835 more codes
| 96415 | 1.7% | 8,700 | $4.58M | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.7% | 5,941 | $4.57M |
| 99284 | Emergency room visit (serious) | 1.6% | 29,213 | $4.36M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 27,606 | $3.78M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.2% | 4,507 | $3.37M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 9,558 | $3.25M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 1.1% | 638 | $3.02M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 56,148 | $2.94M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.0% | 3,425 | $2.72M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 47,539 | $2.59M |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 16,470 | $2.50M |
| 99283 | Emergency room visit (moderate) | <1% | 15,396 | $2.15M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 7,665 | $2.01M |
| G0378 | Hospital observation service, per hour | <1% | 17,341 | $1.98M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 15,471 | $1.90M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 11,956 | $1.80M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 63,757 | $1.70M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 63,783 | $1.68M |
| 74183 | <1% | 6,658 | $1.65M | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 1,288 | $1.57M |
| 20610 | <1% | 10,910 | $1.54M | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,177 | $1.45M |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 1,856 | $1.44M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 10,530 | $1.41M |
| J2357 | Injection, omalizumab, 5 mg | <1% | 1,535 | $1.40M |
| 59025 | Fetal non-stress test | <1% | 5,392 | $1.37M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 3,976 | $1.35M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 23,459 | $1.31M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 10,002 | $1.23M |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 122,718 | $1.23M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 29,644 | $1.23M |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 8,439 | $1.20M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 56,595 | $1.18M |
| J2323 | Injection, natalizumab, 1 mg | <1% | 1,031 | $1.16M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 11,274 | $1.13M |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 21,491 | $1.12M |
| 31579 | <1% | 2,272 | $1.11M | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 653 | $1.10M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,929 | $1.09M |
| 96367 | <1% | 7,854 | $1.08M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,522 | $1.08M |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 2,232 | $1.04M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 27,835 | $1.04M |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 11,341 | $1.03M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,959 | $1.02M |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 7,341 | $1.02M |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 149,192 | $995K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 6,222 | $978K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 49,125 | $893K |
| 72197 | <1% | 3,812 | $878K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 15,031 | $866K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 12,296 | $861K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 2,842 | $852K |
| 76830 | Ultrasound, transvaginal | <1% | 9,555 | $845K |
| 62323 | <1% | 2,101 | $826K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 188,582 | $811K |
| 43235 | <1% | 1,349 | $796K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 9,633 | $789K |
| 85027 | <1% | 186,417 | $756K | |
| 80051 | <1% | 182,251 | $733K | |
| 93971 | <1% | 5,560 | $731K | |
| 31575 | <1% | 4,005 | $724K | |
| 76642 | <1% | 8,491 | $697K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 18,687 | $689K |
| 52000 | <1% | 1,379 | $684K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,667 | $681K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 20,809 | $653K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 3,981 | $648K |
| 80061 | Lipid panel | <1% | 144,780 | $641K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 26,198 | $619K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,665 | $610K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 37,832 | $605K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 34,149 | $597K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 9,031 | $588K |
| 76813 | <1% | 4,263 | $588K | |
| J9299 | Injection, nivolumab, 1 mg | <1% | 211 | $587K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,696 | $563K |
| 76536 | <1% | 5,830 | $556K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,374 | $555K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,788 | $555K |
| 76801 | <1% | 4,356 | $540K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 16,112 | $530K |
| 31231 | <1% | 3,262 | $525K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,112 | $525K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 17,188 | $524K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 33,627 | $521K |
| 97161 | <1% | 8,329 | $494K | |
| 96416 | <1% | 2,048 | $492K | |
| 99219 | <1% | 2,284 | $491K | |
| 64615 | <1% | 1,918 | $481K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,565 | $479K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | <1% | 448 | $476K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 17,772 | $463K |
| J2350 | Injection, ocrelizumab, 1 mg | <1% | 44 | $449K |
| J9312 | Injection, rituximab, 10 mg | <1% | 197 | $436K |
| 91200 | <1% | 5,454 | $432K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 7,615 | $403K |
| 71250 | <1% | 7,054 | $401K | |
| 83735 | <1% | 109,199 | $397K | |
| 70496 | <1% | 1,998 | $387K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,880 | $387K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,299 | $385K |
| 87517 | <1% | 13,329 | $383K | |
| 36430 | <1% | 1,458 | $378K | |
| S9485 | Crisis intervention mental health services, per diem | <1% | 814 | $371K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 19,495 | $369K |
| 76775 | <1% | 4,113 | $366K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 68,486 | $366K |
| 20611 | <1% | 1,342 | $366K | |
| 58300 | <1% | 1,319 | $357K | |
| 86481 | <1% | 5,812 | $352K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 479 | $351K |
| 97162 | <1% | 6,574 | $349K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,764 | $338K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 5,697 | $335K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,895 | $335K |
| 97803 | <1% | 4,549 | $317K | |
| 82565 | <1% | 286,189 | $317K | |
| 94010 | <1% | 8,142 | $304K | |
| 86803 | <1% | 30,314 | $304K | |
| 93970 | <1% | 1,582 | $303K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 2,451 | $298K |
| 84439 | <1% | 50,050 | $295K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,538 | $288K |
| 86780 | <1% | 27,042 | $286K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 535 | $285K |
| 82728 | <1% | 36,298 | $284K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,171 | $282K |
| 90686 | <1% | 15,535 | $277K | |
| 20550 | <1% | 1,795 | $272K | |
| 93017 | <1% | 3,559 | $270K | |
| 84460 | <1% | 260,633 | $259K | |
| 72141 | <1% | 1,651 | $258K | |
| 82105 | <1% | 23,001 | $258K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 67,790 | $256K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,578 | $254K |
| 86480 | <1% | 6,095 | $251K | |
| 88307 | <1% | 3,606 | $248K | |
| 84450 | <1% | 246,729 | $236K | |
| 87340 | <1% | 31,590 | $233K | |
| 93320 | <1% | 2,283 | $229K | |
| 82607 | <1% | 29,257 | $229K | |
| 77336 | <1% | 3,273 | $228K | |
| 87536 | <1% | 5,578 | $223K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 3,398 | $222K |
| 92551 | <1% | 2,002 | $217K | |
| 90715 | <1% | 8,676 | $211K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,008 | $208K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 30,287 | $208K |
| 95886 | <1% | 1,117 | $205K | |
| 83970 | <1% | 12,397 | $200K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 1,719 | $199K |
| 86850 | <1% | 29,678 | $196K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 2,529 | $195K |
| 97802 | <1% | 2,873 | $195K | |
| 84153 | <1% | 17,709 | $193K | |
| 77066 | Tomosynthesis, mammo | <1% | 5,708 | $192K |
| 77334 | <1% | 1,038 | $185K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,406 | $185K |
| 96402 | <1% | 3,623 | $182K | |
| 95117 | <1% | 5,206 | $179K | |
| 83880 | <1% | 11,373 | $179K | |
| 81001 | <1% | 88,626 | $177K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 3,623 | $177K |
| 0002A | <1% | 7,093 | $177K | |
| 74178 | <1% | 1,686 | $174K | |
| 84520 | <1% | 257,697 | $173K | |
| 86706 | <1% | 22,600 | $172K | |
| 88342 | <1% | 7,847 | $170K | |
| 93296 | <1% | 6,539 | $170K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,672 | $169K |
| 84484 | <1% | 21,492 | $168K | |
| 84466 | <1% | 24,683 | $165K | |
| 77065 | Tomosynthesis, mammo | <1% | 3,846 | $161K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,231 | $161K |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 125 | $161K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 17,825 | $160K |
| 20553 | <1% | 1,306 | $159K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,003 | $156K |
| 84702 | <1% | 12,261 | $150K | |
| 85610 | <1% | 63,910 | $150K | |
| Q3014 | Telehealth originating site facility fee | <1% | 43,190 | $150K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 29,628 | $150K |
| 17110 | <1% | 1,077 | $148K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 15,827 | $145K |
| 58301 | <1% | 586 | $141K | |
| 93325 | <1% | 2,755 | $141K | |
| 82247 | <1% | 140,599 | $141K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 109,009 | $138K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,867 | $135K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 20,140 | $135K |
| 0001A | <1% | 6,904 | $134K | |
| 86900 | <1% | 30,797 | $130K | |
| 76937 | <1% | 1,278 | $130K | |
| 87522 | Neg quan hep c or qual rna | <1% | 4,612 | $128K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 31,934 | $127K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,968 | $126K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,512 | $123K |
| 83655 | <1% | 10,488 | $123K | |
| 88341 | <1% | 4,548 | $122K | |
| 87102 | <1% | 18,902 | $120K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,545 | $120K |
| 83690 | <1% | 27,396 | $119K | |
| 82043 | <1% | 40,448 | $119K | |
| 77062 | <1% | 1,870 | $119K | |
| 90750 | <1% | 2,125 | $118K | |
| 82947 | <1% | 94,307 | $118K | |
| 86762 | <1% | 10,148 | $115K | |
| 67228 | <1% | 381 | $114K | |
| 81025 | <1% | 20,909 | $114K | |
| 82784 | <1% | 12,454 | $113K | |
| 11102 | <1% | 376 | $111K | |
| 76942 | <1% | 2,225 | $111K | |
| 86704 | <1% | 13,879 | $108K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 40,210 | $105K |
| 84075 | <1% | 143,462 | $103K | |
| 80069 | <1% | 31,044 | $102K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,494 | $101K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,716 | $99K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,126 | $97K |
| 83540 | <1% | 27,961 | $97K | |
| 83605 | <1% | 12,969 | $97K | |
| 86140 | <1% | 30,705 | $97K | |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 210 | $96K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 35,052 | $95K |
| 85730 | <1% | 24,920 | $94K | |
| 86787 | <1% | 9,889 | $93K | |
| 80053 | Comprehensive metabolic panel | <1% | 18,035 | $93K |
| 86360 | <1% | 4,879 | $91K | |
| 82040 | <1% | 72,089 | $89K | |
| 73562 | <1% | 8,525 | $88K | |
| 82746 | <1% | 10,609 | $86K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,599 | $86K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,324 | $86K |
| 86901 | <1% | 30,591 | $85K | |
| 72100 | <1% | 4,100 | $84K | |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 35 | $84K |
| 84403 | <1% | 5,960 | $84K | |
| 88112 | <1% | 3,119 | $83K | |
| 74174 | <1% | 682 | $82K | |
| 87205 | <1% | 24,304 | $82K | |
| 94729 | <1% | 3,394 | $81K | |
| 90836 | <1% | 992 | $81K | |
| 77386 | <1% | 370 | $80K | |
| 92134 | <1% | 9,435 | $79K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,337 | $79K |
| 76882 | <1% | 859 | $79K | |
| 86003 | <1% | 1,097 | $78K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 287 | $77K |
| 87081 | <1% | 12,701 | $77K | |
| 11900 | <1% | 393 | $77K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,366 | $76K |
| 99173 | <1% | 1,496 | $76K | |
| 19083 | <1% | 61 | $75K | |
| 77300 | <1% | 431 | $74K | |
| 82378 | <1% | 8,011 | $73K | |
| 82570 | <1% | 26,718 | $72K | |
| ATP07 | <1% | 12,069 | $71K | |
| 73030 | <1% | 7,538 | $71K | |
| 73630 | <1% | 7,243 | $70K | |
| ATP14 | <1% | 10,428 | $69K | |
| 64405 | <1% | 249 | $69K | |
| 83520 | <1% | 6,980 | $69K | |
| 96401 | <1% | 1,942 | $69K | |
| J2704 | Injection, propofol, 10 mg | <1% | 32,664 | $67K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,300 | $65K |
| 84100 | <1% | 75,770 | $63K | |
| 84146 | <1% | 4,635 | $63K | |
| 80197 | <1% | 11,604 | $61K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 217 | $61K |
| 87040 | <1% | 5,628 | $61K | |
| 58100 | <1% | 216 | $60K | |
| 87186 | <1% | 11,755 | $60K | |
| 83001 | <1% | 4,505 | $60K | |
| 73130 | <1% | 5,961 | $59K | |
| 11100 | <1% | 404 | $57K | |
| 93351 | <1% | 1,184 | $57K | |
| 17311 | <1% | 167 | $56K | |
| ATP09 | <1% | 9,705 | $55K | |
| 51741 | <1% | 1,317 | $55K | |
| 87799 | <1% | 3,304 | $55K | |
| 99201 | <1% | 475 | $55K | |
| 0012A | <1% | 1,801 | $55K | |
| 99385 | <1% | 584 | $54K | |
| 90677 | <1% | 1,500 | $54K | |
| 0011A | <1% | 1,776 | $54K | |
| 92083 | <1% | 4,135 | $54K | |
| 70491 | <1% | 558 | $54K | |
| 72158 | <1% | 362 | $54K | |
| 86160 | <1% | 3,969 | $53K | |
| 82310 | <1% | 62,968 | $53K | |
| 87338 | <1% | 4,805 | $53K | |
| 86038 | <1% | 6,625 | $52K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 982 | $52K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,875 | $52K |
| 86708 | <1% | 6,409 | $51K | |
| 84480 | <1% | 5,788 | $51K | |
| 77049 | <1% | 130 | $51K | |
| 90837 | Psychotherapy session, about an hour | <1% | 798 | $50K |
| 71271 | <1% | 1,107 | $50K | |
| J3490 | Unclassified drugs | <1% | 2,489 | $50K |
| 73610 | <1% | 5,925 | $50K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 629 | $49K |
| 87077 | <1% | 9,633 | $48K | |
| 73221 | <1% | 248 | $47K | |
| 86235 | <1% | 1,343 | $47K | |
| 36591 | <1% | 8,223 | $47K | |
| J9310 | Injection, rituximab, 100 mg | <1% | 39 | $47K |
| 73502 | <1% | 4,865 | $47K | |
| 86765 | <1% | 5,292 | $47K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 211 | $46K |
| ATP12 | <1% | 8,018 | $46K | |
| 99220 | <1% | 102 | $46K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17,512 | $46K |
| 73560 | <1% | 3,027 | $45K | |
| 88148 | <1% | 5,488 | $45K | |
| 76820 | <1% | 761 | $45K | |
| 82670 | <1% | 2,254 | $45K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,813 | $44K |
| 99218 | <1% | 326 | $44K | |
| 81003 | <1% | 30,801 | $42K | |
| 64450 | <1% | 152 | $42K | |
| 77290 | <1% | 218 | $42K | |
| 86735 | <1% | 4,762 | $41K | |
| J3111 | Injection, romosozumab-aqqg, 1 mg | <1% | 37 | $40K |
| 92133 | <1% | 5,207 | $40K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 33 | $39K |
| 84156 | <1% | 18,950 | $39K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,871 | $38K |
| 93923 | <1% | 764 | $38K | |
| 84165 | <1% | 8,244 | $37K | |
| 84132 | <1% | 38,557 | $36K | |
| 88185 | <1% | 340 | $35K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13,333 | $35K |
| 93975 | <1% | 336 | $34K | |
| 82803 | <1% | 2,155 | $34K | |
| G0008 | Administration of influenza virus vaccine | <1% | 9,382 | $34K |
| 77002 | <1% | 600 | $33K | |
| ATP13 | <1% | 6,945 | $33K | |
| 88173 | <1% | 1,088 | $33K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,897 | $33K |
| 86304 | <1% | 2,902 | $33K | |
| 72156 | <1% | 91 | $32K | |
| 99442 | <1% | 1,775 | $32K | |
| 88304 | <1% | 3,884 | $32K | |
| 73110 | <1% | 3,630 | $32K | |
| ATP06 | <1% | 8,789 | $32K | |
| 58558 | <1% | 14 | $32K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 3,537 | $31K |
| 86832 | <1% | 459 | $31K | |
| 96417 | <1% | 5,643 | $31K | |
| 86255 | <1% | 3,308 | $31K | |
| J0485 | Injection, belatacept, 1 mg | <1% | 132 | $31K |
| 77412 | <1% | 202 | $30K | |
| 80050 | General health panel | <1% | 1,871 | $30K |
| 86923 | <1% | 1,232 | $29K | |
| 99397 | <1% | 1,371 | $29K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 217 | $29K |
| 90732 | <1% | 1,574 | $29K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 33,863 | $29K |
| ATP11 | <1% | 5,811 | $28K | |
| 70498 | <1% | 1,227 | $28K | |
| 72040 | <1% | 1,676 | $28K | |
| 83516 | <1% | 1,721 | $28K | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 14,952 | $28K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,363 | $28K |
| 87497 | <1% | 1,428 | $27K | |
| 69210 | <1% | 689 | $27K | |
| 99406 | <1% | 1,769 | $27K | |
| 86831 | <1% | 1,194 | $27K | |
| 83002 | <1% | 1,926 | $27K | |
| 85379 | <1% | 3,750 | $27K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,181 | $26K |
| ATP04 | <1% | 7,503 | $26K | |
| 87088 | <1% | 5,239 | $26K | |
| 87070 | <1% | 4,917 | $26K | |
| 64400 | <1% | 56 | $26K | |
| 96368 | <1% | 1,496 | $25K | |
| ATP03 | <1% | 13,435 | $25K | |
| 86830 | <1% | 1,103 | $25K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 37 | $25K |
| 83718 | <1% | 4,576 | $25K | |
| 86359 | <1% | 1,389 | $24K | |
| 97165 | <1% | 263 | $24K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 599 | $24K |
| 88312 | <1% | 1,411 | $24K | |
| ATP15 | <1% | 3,760 | $24K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 92 | $24K |
| 84270 | <1% | 1,385 | $24K | |
| 81002 | <1% | 10,247 | $24K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,149 | $24K |
| ATP08 | <1% | 5,751 | $23K | |
| 86592 | <1% | 6,651 | $23K | |
| 99205 | Prolong outpt/office vis | <1% | 152 | $23K |
| 86833 | <1% | 426 | $23K | |
| 97166 | <1% | 356 | $23K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 22,264 | $23K |
| 86301 | <1% | 2,615 | $23K | |
| 96040 | <1% | 2,378 | $22K | |
| ATP10 | <1% | 4,667 | $22K | |
| 17000 | <1% | 628 | $22K | |
| 87046 | <1% | 2,411 | $22K | |
| ATP05 | <1% | 4,476 | $22K | |
| 83615 | <1% | 26,900 | $22K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 78 | $22K |
| 82550 | <1% | 17,716 | $22K | |
| 82533 | <1% | 1,889 | $22K | |
| 80299 | <1% | 2,793 | $22K | |
| 82397 | <1% | 2,923 | $22K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,496 | $21K |
| 36561 | <1% | 26 | $21K | |
| 90662 | <1% | 3,634 | $21K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 1,299 | $20K |
| 86618 | <1% | 1,245 | $20K | |
| 90746 | <1% | 774 | $20K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 7,386 | $20K |
| G0127 | Trimming of dystrophic nails, any number | <1% | 3,386 | $20K |
| 90670 | <1% | 676 | $19K | |
| 86769 | <1% | 960 | $19K | |
| 83020 | <1% | 1,375 | $19K | |
| 64493 | <1% | 27 | $19K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 27 | $19K |
| 90870 | <1% | 98 | $19K | |
| 77061 | <1% | 263 | $18K | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 295 | $18K |
| 91300 | <1% | 5,969 | $18K | |
| 99152 | <1% | 7,932 | $18K | |
| 83010 | <1% | 2,814 | $18K | |
| 85007 | <1% | 8,846 | $18K | |
| 86800 | <1% | 1,633 | $18K | |
| C1769 | Guide wire | <1% | 5,252 | $18K |
| 83521 | <1% | 2,238 | $17K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,035 | $17K |
| 84550 | <1% | 24,601 | $17K | |
| 76770 | <1% | 135 | $17K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 14 | $17K |
| 87045 | <1% | 2,363 | $17K | |
| 11104 | <1% | 28 | $17K | |
| 20552 | <1% | 98 | $17K | |
| 91322 | <1% | 279 | $17K | |
| 84295 | <1% | 25,593 | $17K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 10,469 | $17K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 1,461 | $16K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 7,100 | $16K |
| 85045 | <1% | 7,121 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,697 | $16K |
| 90739 | <1% | 216 | $15K | |
| 74230 | <1% | 187 | $15K | |
| 96376 | <1% | 6,062 | $15K | |
| 82150 | <1% | 3,832 | $15K | |
| 93926 | <1% | 48 | $15K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 3,044 | $15K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 58 | $15K |
| 80076 | <1% | 5,182 | $14K | |
| 99443 | <1% | 385 | $14K | |
| 0003A | <1% | 736 | $14K | |
| 51798 | <1% | 2,970 | $14K | |
| 84166 | <1% | 1,905 | $14K | |
| 76377 | <1% | 5,007 | $14K | |
| 96523 | <1% | 652 | $14K | |
| 96411 | <1% | 2,065 | $14K | |
| 82248 | <1% | 15,807 | $14K | |
| 86225 | <1% | 1,612 | $13K | |
| 77295 | <1% | 32 | $13K | |
| ATP02 | <1% | 4,308 | $13K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,859 | $13K |
| J1815 | Injection, insulin, per 5 units | <1% | 2,407 | $12K |
| 86430 | <1% | 3,120 | $12K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,871 | $12K |
| 82465 | <1% | 5,948 | $12K | |
| 76870 | <1% | 130 | $12K | |
| ATP16 | <1% | 1,864 | $12K | |
| 83721 | <1% | 2,670 | $11K | |
| 49083 | <1% | 52 | $11K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 5,769 | $11K |
| 87209 | <1% | 930 | $11K | |
| 90734 | <1% | 162 | $11K | |
| 82553 | <1% | 1,959 | $11K | |
| 88313 | <1% | 648 | $11K | |
| 86200 | <1% | 1,320 | $11K | |
| 88184 | <1% | 357 | $11K | |
| 93308 | <1% | 64 | $11K | |
| 94060 | <1% | 85 | $11K | |
| 84432 | <1% | 844 | $11K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,663 | $10K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,217 | $10K |
| 51784 | <1% | 85 | $10K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 303 | $10K |
| 74181 | <1% | 14 | $10K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 13 | $10K |
| 87147 | <1% | 2,274 | $10K | |
| 84425 | <1% | 584 | $10K | |
| ATP17 | <1% | 1,763 | $10K | |
| 92226 | <1% | 1,301 | $9K | |
| 73590 | <1% | 1,323 | $9K | |
| 0124A | <1% | 452 | $9K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 160 | $9K |
| 76000 | <1% | 371 | $9K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 1,772 | $9K |
| 85652 | <1% | 5,680 | $9K | |
| 82785 | <1% | 762 | $9K | |
| 86376 | <1% | 804 | $8K | |
| 93880 | <1% | 82 | $8K | |
| 90651 | <1% | 75 | $8K | |
| 57454 | <1% | 24 | $8K | |
| 92611 | <1% | 132 | $8K | |
| 86707 | <1% | 619 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 214 | $8K |
| 77073 | <1% | 1,362 | $8K | |
| 86580 | <1% | 352 | $7K | |
| 94727 | <1% | 231 | $7K | |
| 97760 | <1% | 117 | $7K | |
| 93280 | <1% | 1,095 | $7K | |
| 70543 | <1% | 32 | $7K | |
| 92202 | <1% | 446 | $7K | |
| 84155 | <1% | 13,174 | $7K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 68 | $7K |
| 73080 | <1% | 719 | $6K | |
| 10060 | <1% | 61 | $6K | |
| 73140 | <1% | 439 | $6K | |
| 0054A | <1% | 237 | $6K | |
| 67210 | <1% | 31 | $6K | |
| 94726 | <1% | 99 | $6K | |
| 87075 | <1% | 1,289 | $6K | |
| 83921 | <1% | 638 | $6K | |
| 86039 | <1% | 874 | $6K | |
| 87350 | <1% | 515 | $6K | |
| 0013A | <1% | 261 | $6K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,830 | $6K |
| 82627 | <1% | 312 | $6K | |
| 91065 | <1% | 71 | $6K | |
| 74018 | <1% | 507 | $6K | |
| 82805 | <1% | 138 | $6K | |
| 96127 | <1% | 98 | $6K | |
| 70486 | <1% | 174 | $6K | |
| 84703 | <1% | 849 | $5K | |
| 73564 | <1% | 1,535 | $5K | |
| 11981 | <1% | 29 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,941 | $5K |
| 92557 | <1% | 219 | $5K | |
| 86677 | <1% | 500 | $5K | |
| 96377 | <1% | 1,226 | $5K | |
| 88271 | <1% | 70 | $5K | |
| 85014 | <1% | 3,396 | $5K | |
| 99495 | <1% | 109 | $5K | |
| 90716 | <1% | 69 | $5K | |
| 86381 | <1% | 420 | $5K | |
| 86300 | <1% | 646 | $5K | |
| 75561 | <1% | 14 | $5K | |
| 82435 | <1% | 6,820 | $5K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,843 | $5K |
| 20605 | <1% | 29 | $5K | |
| 82948 | <1% | 1,936 | $5K | |
| 92250 | <1% | 579 | $5K | |
| 85018 | <1% | 4,105 | $5K | |
| 87116 | <1% | 726 | $5K | |
| 90480 | <1% | 247 | $5K | |
| 72070 | <1% | 218 | $5K | |
| 84681 | <1% | 433 | $4K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 54 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 448 | $4K |
| 97116 | <1% | 81 | $4K | |
| 90656 | <1% | 339 | $4K | |
| 87496 | <1% | 135 | $4K | |
| 95885 | <1% | 13 | $4K | |
| 0064A | <1% | 123 | $4K | |
| 88360 | <1% | 63 | $4K | |
| 82977 | <1% | 4,923 | $4K | |
| 82962 | <1% | 2,531 | $4K | |
| 96132 | <1% | 54 | $4K | |
| 82960 | <1% | 909 | $4K | |
| 87015 | <1% | 1,042 | $4K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,325 | $4K |
| 86355 | <1% | 280 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,619 | $4K |
| 0134A | <1% | 167 | $4K | |
| 77001 | <1% | 281 | $4K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 13 | $4K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 29 | $4K |
| 0071A | <1% | 88 | $4K | |
| 82172 | <1% | 455 | $4K | |
| 86334 | <1% | 461 | $4K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 776 | $4K |
| 0053A | <1% | 94 | $4K | |
| 86870 | <1% | 136 | $4K | |
| 96409 | <1% | 107 | $4K | |
| 87493 | <1% | 691 | $4K | |
| 93299 | <1% | 197 | $3K | |
| 86777 | <1% | 488 | $3K | |
| 90632 | <1% | 122 | $3K | |
| 89051 | <1% | 1,041 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 576 | $3K |
| 0072A | <1% | 76 | $3K | |
| 73565 | <1% | 265 | $3K | |
| 87252 | <1% | 143 | $3K | |
| 86644 | <1% | 349 | $3K | |
| 82374 | <1% | 3,998 | $3K | |
| 51729 | <1% | 14 | $3K | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 141 | $3K |
| 73552 | <1% | 555 | $3K | |
| 36902 | <1% | 12 | $3K | |
| 75574 | <1% | 13 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 8,809 | $3K |
| 97113 | <1% | 41 | $3K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 444 | $3K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,667 | $3K |
| 0296T | <1% | 54 | $2K | |
| 87177 | <1% | 445 | $2K | |
| 86015 | <1% | 417 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,065 | $2K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 103 | $2K |
| 86357 | <1% | 149 | $2K | |
| 76818 | <1% | 62 | $2K | |
| 82810 | <1% | 448 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 2,503 | $2K |
| 93271 | <1% | 24 | $2K | |
| 87486 | <1% | 93 | $2K | |
| 87581 | <1% | 93 | $2K | |
| 78306 | <1% | 13 | $2K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,368 | $2K |
| 99441 | <1% | 352 | $2K | |
| 87206 | <1% | 524 | $2K | |
| 86696 | <1% | 112 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,048 | $2K |
| 87902 | <1% | 14 | $2K | |
| 92136 | <1% | 110 | $2K | |
| 86147 | <1% | 62 | $2K | |
| 72157 | <1% | 15 | $2K | |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | <1% | 12 | $2K |
| 86645 | <1% | 237 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 6,061 | $2K |
| 80164 | <1% | 350 | $2K | |
| J3470 | Injection, hyaluronidase, up to 150 units | <1% | 238 | $2K |
| 88264 | <1% | 26 | $2K | |
| 84630 | <1% | 207 | $2K | |
| 90707 | <1% | 64 | $2K | |
| 86364 | <1% | 303 | $2K | |
| 86665 | <1% | 75 | $2K | |
| 72110 | <1% | 164 | $2K | |
| ATP18 | <1% | 280 | $2K | |
| 72170 | <1% | 273 | $2K | |
| 88311 | <1% | 288 | $2K | |
| 86695 | <1% | 124 | $2K | |
| 73523 | <1% | 40 | $2K | |
| 86880 | <1% | 344 | $1K | |
| 86141 | <1% | 162 | $1K | |
| 87210 | <1% | 432 | $1K | |
| 91307 | <1% | 131 | $1K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,675 | $1K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 27 | $1K |
| 98967 | <1% | 76 | $1K | |
| 93225 | <1% | 13 | $1K | |
| 93226 | <1% | 13 | $1K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 31 | $1K |
| 93356 | <1% | 823 | $1K | |
| 64447 | <1% | 12 | $1K | |
| 97163 | <1% | 13 | $1K | |
| 0052A | <1% | 28 | $1K | |
| 87529 | <1% | 26 | $1K | |
| 82610 | <1% | 116 | $1K | |
| C9399 | Unclassified drugs or biologicals | <1% | 117 | $1K |
| 88275 | <1% | 15 | $1K | |
| 92504 | <1% | 26 | $1K | |
| 84207 | <1% | 46 | $1K | |
| 88309 | <1% | 15 | $1K | |
| 88302 | <1% | 192 | $991.95 | |
| 90674 | <1% | 325 | $914.15 | |
| 92020 | <1% | 364 | $912.31 | |
| 90691 | <1% | 12 | $912.24 | |
| 99221 | <1% | 81 | $901.94 | |
| 83993 | <1% | 90 | $882.81 | |
| 86146 | <1% | 14 | $875.55 | |
| 86037 | <1% | 39 | $832.92 | |
| 72146 | <1% | 15 | $814.66 | |
| 84478 | <1% | 478 | $780.32 | |
| 86709 | <1% | 113 | $761.01 | |
| 85384 | <1% | 101 | $747.15 | |
| 0051A | <1% | 18 | $733.92 | |
| 86705 | <1% | 183 | $726.60 | |
| 86664 | <1% | 75 | $726.43 | |
| 80178 | <1% | 147 | $714.04 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 892 | $698.08 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 328 | $695.05 |
| 88300 | <1% | 142 | $684.51 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 2,593 | $664.32 |
| 85049 | <1% | 518 | $663.41 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 352 | $650.20 |
| 90714 | <1% | 39 | $648.98 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 40 | $640.20 |
| 86692 | <1% | 47 | $639.60 | |
| 11721 | <1% | 43 | $638.07 | |
| 84300 | <1% | 310 | $635.19 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 515 | $584.30 |
| C7901 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 250 | $529.06 |
| 87625 | <1% | 31 | $513.41 | |
| 84445 | <1% | 12 | $510.29 | |
| 93976 | <1% | 12 | $495.85 | |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | <1% | 13 | $485.66 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 118 | $480.80 |
| 73060 | <1% | 56 | $478.18 | |
| 82010 | <1% | 77 | $441.44 | |
| 85705 | <1% | 53 | $431.40 | |
| 82088 | <1% | 13 | $431.28 | |
| 85613 | <1% | 53 | $429.17 | |
| 86431 | <1% | 143 | $410.65 | |
| 90633 | <1% | 12 | $401.88 | |
| 80047 | <1% | 49 | $387.53 | |
| 36416 | <1% | 908 | $379.26 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 189 | $378.82 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 465 | $371.17 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 510 | $365.36 |
| 83519 | <1% | 19 | $364.86 | |
| 87269 | <1% | 56 | $361.44 | |
| 84481 | <1% | 28 | $343.62 | |
| 87272 | <1% | 56 | $337.92 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 449 | $330.36 |
| 82330 | <1% | 55 | $318.36 | |
| 99386 | <1% | 15 | $314.14 | |
| 84436 | <1% | 38 | $306.46 | |
| 86711 | <1% | 133 | $305.41 | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 35 | $280.30 |
| 84244 | <1% | 13 | $271.60 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 197 | $267.28 |
| 74019 | <1% | 12 | $257.28 | |
| 82955 | <1% | 32 | $256.80 | |
| 73700 | <1% | 15 | $253.14 | |
| 80179 | <1% | 31 | $246.60 | |
| 87467 | <1% | 19 | $246.35 | |
| 82077 | <1% | 126 | $243.68 | |
| 83935 | <1% | 88 | $234.14 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 15 | $232.34 |
| 51702 | <1% | 57 | $223.17 | |
| 91312 | <1% | 376 | $222.36 | |
| 83789 | <1% | 13 | $222.27 | |
| 82103 | <1% | 24 | $216.17 | |
| 88142 | <1% | 12 | $214.44 | |
| 80158 | <1% | 43 | $204.82 | |
| 86336 | <1% | 12 | $192.84 | |
| 76514 | <1% | 50 | $191.70 | |
| 91305 | <1% | 466 | $185.37 | |
| 83026 | <1% | 55 | $184.08 | |
| 86335 | <1% | 12 | $181.23 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 332 | $177.27 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 14 | $170.61 |
| 36592 | <1% | 42 | $157.60 | |
| 93000 | <1% | 312 | $148.70 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 201 | $135.12 |
| 84402 | <1% | 12 | $132.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,132 | $125.42 |
| 93246 | <1% | 47 | $123.44 | |
| 84590 | <1% | 12 | $122.88 | |
| 82525 | <1% | 14 | $120.45 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 40 | $115.16 |
| 83930 | <1% | 42 | $114.57 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,260 | $113.63 |
| 83525 | <1% | 13 | $110.88 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 126 | $108.95 |
| 84157 | <1% | 45 | $108.83 | |
| C1781 | Mesh (implantable) | <1% | 12 | $107.47 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 436 | $106.08 |
| 83037 | <1% | 52 | $103.23 | |
| 11719 | <1% | 17 | $102.62 | |
| 87899 | <1% | 12 | $102.34 | |
| 80321 | <1% | 517 | $88.40 | |
| 93270 | <1% | 12 | $76.40 | |
| 85732 | <1% | 13 | $74.23 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 171 | $72.23 |
| 92567 | <1% | 107 | $70.97 | |
| 46600 | <1% | 100 | $63.12 | |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 12 | $62.43 |
| G0010 | Administration of hepatitis b vaccine | <1% | 98 | $60.30 |
| 86308 | <1% | 12 | $50.27 | |
| P3000 | Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision | <1% | 21 | $45.84 |
| 82270 | <1% | 14 | $42.77 | |
| 13132 | <1% | 13 | $42.15 | |
| C1729 | Catheter, drainage | <1% | 533 | $40.12 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 55 | $39.08 |
| 80348 | <1% | 776 | $35.90 | |
| 90678 | <1% | 20 | $26.84 | |
| 73090 | <1% | 13 | $20.14 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 271 | $19.76 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 238 | $19.65 |
| 89060 | <1% | 12 | $14.76 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 465 | $10.66 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 88 | $9.07 |
| 98968 | <1% | 15 | $7.78 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 30 | $3.77 |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg | <1% | 123 | $0.02 |
| 91313 | <1% | 121 | $0.02 | |
| 91306 | <1% | 105 | $0.01 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 1,014 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 89 | $0.00 |
| 80346 | 0% | 87 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 1,101 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 1,558 | $0.00 |
| 90649 | 0% | 211 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 150 | $0.00 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 250 | $0.00 |
| 17003 | 0% | 161 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 109 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 14 | $0.00 |
| 93321 | 0% | 28 | $0.00 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 92 | $0.00 |
| 51701 | 0% | 12 | $0.00 | |
| 80143 | 0% | 31 | $0.00 | |
| 69209 | 0% | 17 | $0.00 | |
| 80373 | 0% | 31 | $0.00 | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 107 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 44 | $0.00 |
| 95970 | 0% | 29 | $0.00 | |
| 72050 | 0% | 14 | $0.00 | |
| 96138 | 0% | 14 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 43 | $0.00 |
| 80361 | 0% | 87 | $0.00 | |
| 96133 | 0% | 29 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 12 | $0.00 |
| G0204 | Diagnostic mammography, including computer-aided detection (cad) when performed; bilateral | 0% | 15 | $0.00 |
| 91301 | 0% | 2,423 | $0.00 | |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 195 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 449 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 124 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 50 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg | 0% | 93 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 400 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 60 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 14 | $0.00 |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | 0% | 56 | $0.00 |
| G0206 | Diagnostic mammography, including computer-aided detection (cad) when performed; unilateral | 0% | 15 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 104 | $0.00 |
| 51797 | 0% | 25 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 54 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 12 | $0.00 |
| 17312 | 0% | 13 | $0.00 | |
| 96139 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBHOGADI, SATISH (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Beth Israel Deaconess Medical Center, INC | Chestnut Hill, MA | $506.94 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.